Teclison Ltd.   Report issue

For profit Phase 2
Founded: Richmond VA United States (2015)

Organization Overview

First Clinical Trial
2015
NCT02174549
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Teclison Limited | Teclison Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Colorectal Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 1)

Liver Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4